Skip to content
Home/Companies/Life Sciences/Sim&Cure

Sim&Cure

Life Sciences·France·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Sim&Cure?

Sim&Cure is currently owned by Elaia Partners through Elaia Delta Fund (2017 vintage), since 2019.

Hand-verified · updated 2026-04-21

Elaia Partners
Investor
Elaia Partners
Elaia Delta Fund · 2017 · VC

Key facts

HQFrance
SectorLife Sciences

More from Elaia Delta Fund

Other portfolio companies in the same fund.

Cien
Cien
Active
AI/MLSpain· 2019
Eikosim
Eikosim
Active
Data & AnalyticsFrance· 2019
Heuritech
Exited 2024
AI/MLSpain· 2019
to
Hyperlex
Exited 2022
AI/MLFrance· 2019
to
Lybero
Lybero
Exited 2024
CybersecurityFrance· 2019
Mirakl
Mirakl
Active
SaaSFrance· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Sim&Cure

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Sim&Cure?

0 strategic and 120financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Sim&Cure.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue